FGF19 and metabolic dysfunction-associated steatotic liver disease: Our group of PBC women also showed reduced levels of FGF19 than CTRL but similar to patients with NAFLD, probably due to optimal disease control and absence of cirrhosis; indeed, FGF19 serum levels are elevated in PBC non‐responders to UDCA or with advanced fibrosis, but decrease in UDCA responders.21